Int J Oral Biol.  2024 Sep;49(3):53-60. 10.11620/IJOB.2024.49.3.53.

Nicotinamide as a therapeutic agent for bone diseases

• Yoon H
• Kim WJ
• Cho YD
• Ryoo HM

• KMID: 2562647
• DOI: http://doi.org/10.11620/IJOB.2024.49.3.53

Abstract

Nicotinamide (NAM), a water-soluble derivative of vitamin B3, has emerged as a potential therapeutic agent for bonerelated disorders. In particular, it promotes bone metabolism and alleviates delayed tooth eruptions associated with cleidocranial dysplasia (CCD). NAM serves as a precursor for nicotinamide adenine dinucleotide, a key coenzyme involved in cellular metabolism that plays an essential role in oxidative phosphorylation and mitochondrial function. Recent research has highlighted the capacity of NAM to enhance osteogenic differentiation and regulate the interaction between osteoblasts and osteoclasts, which is critical for maintaining bone homeostasis. Moreover, the effect of NAM in preventing delayed tooth eruptions in CCD models underscores its potential as a noninvasive therapeutic option. Considering its safety profile and therapeutic potential, NAM is a promising candidate for longterm treatment of bone diseases and prevention of age-related bone disorders.

Keyword

Nicotinamide; Tooth eruption; Cleidocranial dysplasia; Mitochondria; Osteoblasts